Abstract
The scale-up and the economic feasibility of the synthesis of St-MMA-GMA-PEGMA particles biofunctionalized with HSA were studied. First, the geometrical similarity of laboratory and pilot plant reactors was checked to develop the scale up of the process according to a criterion of partial similarity. The selected criterion was constant Re number. Then, a reaction in the pilot plant scale was carried out, confirming the suitability of the scale-up criterion, since particles with similar characteristics (same particle size with a deviation of just 6%) and functional groups were obtained. Finally, the design of an industrial plant able to produce 581 Tm/year of HSA functionalized St-MMA-GMA-PEGMA particles was addressed. The economic feasibility of this plant was confirmed by a value of internal rate of return (IRR) of 14.8% and a net present value (NPV) of 5452 M€, with a payback time between six and seven years, for the price of a cartridge 25% lower than that from the current treatments for bilirubin removal from patients with liver failure.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
